SCHEMBL5357446

SCHEMBL5357446

CC(C)(C)Cc1nc(N)nc(Cl)c1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
HRH4 Q9H3N8 1/20 0.33
NUDT1 P36639 1/20 0.33
MEN1 O00255 1/20 0.31
SLC22A1 O15245 1/20 0.31
ALDH1A1 P00352 1/20 0.31
DHFR P00374 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
HEXA P06865 1/20 0.31
HEXB P07686 1/20 0.31
CYP3A4 P08684 1/20 0.31
HTR1A P08908 1/20 0.31
ADRA2A P08913 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
HTR2A P28223 1/20 0.31
ADRA1A P35348 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653958 0.69 MEN1 (0.44) ADORA2AADORA1MEN1LMNACYP1A2
SCHEMBL11596045 0.69 CYP2D6 (0.33) HEXAHEXBCYP2D6TDP1
SCHEMBL11597687 0.69 NOS2 (0.36) ADORA2AADORA1
SCHEMBL11595021 0.67 ALDH1A1 (0.39) ALDH1A1CYP2D6
SCHEMBL10338025 0.65 TLR8 (0.35) ALDH1A1CYP2D6
SCHEMBL26978018 0.65 KDM4E (0.37) ADORA2AADORA1SMN1; SMN2
Hydrochloric Acid SCHEMBL9765064 0.64 TLR8 (0.34) ALDH1A1DHFRCYP2D6
SCHEMBL23175039 0.64 HRH4 (0.55) ADORA2AADORA1HRH4NUDT1LMNA
SCHEMBL9178364 0.64 KDM4E (0.40) ADORA2AADORA1NUDT1MEN1ALDH1A1
SCHEMBL16229312 0.64 L3MBTL1 (0.40) ADORA2AADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285543-B2 Purine inhibitors of fructose-1,6-bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2007-10-23 US disclosed
US-20050277619-A1 Novel purine inhibitors of fructose-1,6-bisphosphatase DANG QUN 2005-12-15 US disclosed
US-6967193-B1 Purine inhibitors of fructose-1,6-bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2005-11-22 US disclosed
US-6284748-B1 ANTIDIABETIC AGENT METABASIS THERAPEUTICS, INC. 2001-09-04 US disclosed
WO-1998039344-A9 NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE 1999-01-21 WO disclosed
WO-1998039344-A1 NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE METABASIS THERAPEUTICS, INC. (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277619-A1 Novel purine inhibitors of fructose-1,6-bisphosphatase FBP1, PNP, PPA1 ADORA2A 319/4885ADORA1 127/4885HRH4 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.